Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSuwakon Wongjaikamen_US
dc.contributor.authorSirinart Kumfuen_US
dc.contributor.authorSiriporn C. Chattipakornen_US
dc.contributor.authorSuthat Fucharoenen_US
dc.contributor.authorNipon Chattipakornen_US
dc.description.abstract© 2015 Elsevier B.V. All rights reserved. Iron overload cardiomyopathy is the major cause of death in transfusion-dependent thalassemia (TDT) patients. Growing evidence demonstrates that combined iron chelators, or the combination of an iron chelator with antioxidant(s) are effective in diminishing myocardial iron deposition and attenuating cardiac dysfunction. This review comprehensively summarizes basic and clinical reports on the therapeutic efficacy of combined iron chelators, or the combination of an iron chelator with antioxidant(s) on the heart. Promising benefits of these treatments in preventing cardiac dysfunction due to iron overload could provide extensive insight into future therapeutic strategies for better treatment and prevention of cardiomyopathy in TDT patients.en_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleCurrent and future treatment strategies for iron overload cardiomyopathyen_US
article.title.sourcetitleEuropean Journal of Pharmacologyen_US
article.volume765en_US Mai Universityen_US Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.